Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma

A retrospective review of 1114 patients

Kamram Darabi, M. Sieber, Mark H. Chaitowitz, L. E. Braitman, W. Tester, V. Diehl

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD). It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH). The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV). This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%). These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma. IDH-patients were older (median 39 vs 31 years; p < 0.001), predominantly male (73% vs 52%; p < 0.001) and more often had involvement of ≥ 3 lymph node areas(LNA) (80% vs 55%; p < 0.001). Histology in IDH was more likely to be mixed cellularity (46.5% vs 23.6%, p < 0.001) or lymphocyte predominant (20 vs 10%, p = 0.003) and less likely nodular sclerosis (25% vs 63%, p < 0.001). In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003). After controlling for age, sex, stage, histology, B-symptoms and involvement of ≥ 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate. Poorer outcomes with iDH as compared to SDH are attributable to its association with known adverse prognostic risk factors, but IDH, in itself, is not an independent adverse prognostic factor for treatment failure or survival.

Original languageEnglish (US)
Pages (from-to)1715-1720
Number of pages6
JournalLeukemia and Lymphoma
Volume46
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Hodgkin Disease
Treatment Failure
Histology
Lymph Nodes
Sclerosis
Germany
Randomized Controlled Trials
Lymphocytes
Survival

Keywords

  • Hodgkin lymphoma
  • Infradiaphragmatic
  • Prognosis
  • Subdiaphragmatic
  • Supradiaphragmatic

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma : A retrospective review of 1114 patients. / Darabi, Kamram; Sieber, M.; Chaitowitz, Mark H.; Braitman, L. E.; Tester, W.; Diehl, V.

In: Leukemia and Lymphoma, Vol. 46, No. 12, 12.2005, p. 1715-1720.

Research output: Contribution to journalArticle

Darabi, Kamram ; Sieber, M. ; Chaitowitz, Mark H. ; Braitman, L. E. ; Tester, W. ; Diehl, V. / Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma : A retrospective review of 1114 patients. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 12. pp. 1715-1720.
@article{2ea24063ffa446688cfbe0743ba09f7a,
title = "Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma: A retrospective review of 1114 patients",
abstract = "Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13{\%} of cases of stage I-II Hodgkin lymphoma (HD). It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH). The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV). This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10{\%}). These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma. IDH-patients were older (median 39 vs 31 years; p < 0.001), predominantly male (73{\%} vs 52{\%}; p < 0.001) and more often had involvement of ≥ 3 lymph node areas(LNA) (80{\%} vs 55{\%}; p < 0.001). Histology in IDH was more likely to be mixed cellularity (46.5{\%} vs 23.6{\%}, p < 0.001) or lymphocyte predominant (20 vs 10{\%}, p = 0.003) and less likely nodular sclerosis (25{\%} vs 63{\%}, p < 0.001). In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95{\%} CI, 1.3-3.4; p = 0.003). After controlling for age, sex, stage, histology, B-symptoms and involvement of ≥ 3 LNA, the adjusted hazard ratio was 1.25 (95{\%} CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate. Poorer outcomes with iDH as compared to SDH are attributable to its association with known adverse prognostic risk factors, but IDH, in itself, is not an independent adverse prognostic factor for treatment failure or survival.",
keywords = "Hodgkin lymphoma, Infradiaphragmatic, Prognosis, Subdiaphragmatic, Supradiaphragmatic",
author = "Kamram Darabi and M. Sieber and Chaitowitz, {Mark H.} and Braitman, {L. E.} and W. Tester and V. Diehl",
year = "2005",
month = "12",
doi = "10.1080/10428190500144847",
language = "English (US)",
volume = "46",
pages = "1715--1720",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Infradiaphragmatic versus supradiaphragmatic Hodgkin lymphoma

T2 - A retrospective review of 1114 patients

AU - Darabi, Kamram

AU - Sieber, M.

AU - Chaitowitz, Mark H.

AU - Braitman, L. E.

AU - Tester, W.

AU - Diehl, V.

PY - 2005/12

Y1 - 2005/12

N2 - Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD). It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH). The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV). This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%). These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma. IDH-patients were older (median 39 vs 31 years; p < 0.001), predominantly male (73% vs 52%; p < 0.001) and more often had involvement of ≥ 3 lymph node areas(LNA) (80% vs 55%; p < 0.001). Histology in IDH was more likely to be mixed cellularity (46.5% vs 23.6%, p < 0.001) or lymphocyte predominant (20 vs 10%, p = 0.003) and less likely nodular sclerosis (25% vs 63%, p < 0.001). In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003). After controlling for age, sex, stage, histology, B-symptoms and involvement of ≥ 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate. Poorer outcomes with iDH as compared to SDH are attributable to its association with known adverse prognostic risk factors, but IDH, in itself, is not an independent adverse prognostic factor for treatment failure or survival.

AB - Infradiaphragmatic Hodgkin lymphoma (IDH) accounts for 4-13% of cases of stage I-II Hodgkin lymphoma (HD). It has been associated with distinct pre-treatment characteristics and outcomes when compared with supradiaphragmatic HD (SDH). The comparison of IDH vs SDH can only be made in early and intermediate stages (I-II), such a comparison is not possible for advanced stages (III-IV). This study retrospectively compared two groups of 1013 patients with stage I-II SDH and 101 patients with IDH (10%). These two sub-groups of patients were treated in 1988-1993 in 2 prospective randomized clinical trials in Germany for early and intermediate stages of Hodgkin lymphoma. IDH-patients were older (median 39 vs 31 years; p < 0.001), predominantly male (73% vs 52%; p < 0.001) and more often had involvement of ≥ 3 lymph node areas(LNA) (80% vs 55%; p < 0.001). Histology in IDH was more likely to be mixed cellularity (46.5% vs 23.6%, p < 0.001) or lymphocyte predominant (20 vs 10%, p = 0.003) and less likely nodular sclerosis (25% vs 63%, p < 0.001). In early-stage unfavorable disease, IDH was associated with a higher treatment failure rate (unadjusted hazard ratio 2, 95% CI, 1.3-3.4; p = 0.003). After controlling for age, sex, stage, histology, B-symptoms and involvement of ≥ 3 LNA, the adjusted hazard ratio was 1.25 (95% CI, 0.65-2.4; p = 0.51) so that IDH was no longer associated with a statistically significant treatment failure rate. Poorer outcomes with iDH as compared to SDH are attributable to its association with known adverse prognostic risk factors, but IDH, in itself, is not an independent adverse prognostic factor for treatment failure or survival.

KW - Hodgkin lymphoma

KW - Infradiaphragmatic

KW - Prognosis

KW - Subdiaphragmatic

KW - Supradiaphragmatic

UR - http://www.scopus.com/inward/record.url?scp=32144454687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32144454687&partnerID=8YFLogxK

U2 - 10.1080/10428190500144847

DO - 10.1080/10428190500144847

M3 - Article

VL - 46

SP - 1715

EP - 1720

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -